A strong piece in Nature Biotechnology highlights a challenge that continues to surface across research institutions: the gap is not a lack of ideas, it is what happens before commercialization even begins.
Technology transfer offices play a critical role, but they are structurally designed to engage once intellectual property is formed and opportunities are more mature. That leaves a large portion of early-stage discovery without the guidance, framing, or support needed to move forward. The result is a familiar pattern where promising innovations stall not because of weak science, but because the system does not engage early enough.
The example from the Weizmann Institute of Science is particularly instructive. Through its BINA program, the institution created a complementary layer upstream of the TTO. Rather than waiting for researchers to arrive with defined commercial pathways, BINA engages earlier, helping scientists explore applications, shape translational plans, and advance toward proof of concept through structured mentorship and milestone-based support.
Importantly, this approach expands who participates in innovation.
By lowering the barrier to entry and engaging earlier in the research lifecycle, programs like BINA bring in researchers who have historically been underrepresented in commercialization efforts, including assistant faculty, postdoctoral researchers, and graduate students. These groups often sit closest to the underlying science, yet are least likely to engage with traditional commercialization pathways. Creating accessible, science-first entry points opens up a much broader portion of the innovation base.
This is where the connection to pre-proof-of-concept programs becomes clear.
Pre-POC efforts are not about commercialization in the traditional sense. They are designed to:
- Help researchers define potential applications
- Introduce early translational thinking
- Reduce uncertainty before formal funding or IP decisions
- Create a clearer path into POC funding, GAP programs, or external partnerships
They represent the earliest intentional point of intervention in the innovation lifecycle.
From the Mind the GAP intelligence, this reinforces that the most effective innovation systems build structured pathways upstream, engaging earlier, broadening participation, and preparing opportunities before they reach formal commercialization stages.
The broader takeaway is clear.
Translation is not a single step managed at the point of commercialization. It is a continuum that begins inside the lab, often well before a project is considered ready.
If institutions want to expand both the volume and quality of innovation reaching real-world application, the focus cannot remain solely on downstream efficiency. It must include building structured, accessible entry points upstream.
Programs like BINA are a clear signal of where this is heading.
Source Story: Nature Biotechnology
https://rdcu.be/fd6bC
Related Topics: gap fund and accelerator programs (GAP), technology commercialization, translational research, startup accelerator, pre-proof of concept funding, capital formation, innovation systems
Explore Mind the GAP:
